Articles related to ANTI-PSYCHOTICS

Explore the latest advances in schizophrenia research and understand how TAAR1 agonism could potentially change the treatment paradigm. Join us in this educational journey.

New research suggests that THC, when obtained from commercial dispensaries, may offer an effective treatment for neuropsychiatric symptoms in dementia patients, potentially reducing the need for antipsychotics.

The FDA’s approval of brexpiprazole for Alzheimer’s-related agitation has sparked a debate over its efficacy and safety, raising concerns that extend beyond this specific drug to the integrity of the regulatory process itself.

This retrospective cohort study provides evidence that the risk profiles for in-hospital adverse events are similar among haloperidol and atypical antipsychotics in older patients with postoperative delirium.

Explore the clinical insights into lumateperone, a second-generation antipsychotic showing promise in treating schizophrenia, and learn how understanding effect sizes can guide your treatment decisions.

The recent FDA approval of brexpiprazole for Alzheimer’s dementia patients has ignited concerns among healthcare professionals. Physicians are urged to carefully consider the drug’s minimal efficacy and increased mortality risk in their treatment decisions.